Chesapeake's New Suit; Wal-Mart's Mexican Mess; Big Lots Goes Bust; BP's Bad Guy; Ratings Ridiculousness.
Senior columnist Adam Feuerstein says M&A is the next big thing in biotech.
The so-called Apple permabulls won't be able to see when the company goes from great to merely good.
Biotech columnist Adam Feuerstein answers readers' questions about health-care companies.
The chief of Berkshire Hathaway has criticized other companies in the past for stock splits and new share issuance.
These stocks, which go ex-dividend Monday, are rated buy at TheStreet Ratings.
U.S. stocks tick back above the flat line Friday after digesting a cooler-than-expected GDP report and mixed earnings data.
Amazon.com beats analysts' earnings estimates; Ford is expected to post results before Friday's opening bell.
Sure, it runs a popular Web site, but the company hasn't proven that it's a sound business.
Here are today's top research calls.